home / stock / xrtx:cc / xrtx:cc news

XRTX:CC News and Press, Xortx Therapeutics Inc. From 05/05/22

Stock Information
Company Name: Xortx Therapeutics Inc.
Stock Symbol: XRTX:CC
Market: TSXVC
Website: xortx.com
Menu
XRTX:CC XRTX:CC Quote XRTX:CC Short XRTX:CC News XRTX:CC Articles XRTX:CC Message Board
Get XRTX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX:CC - XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

● FDA Provides All Clear Notification for IND and Bridging Pharmacokinetics Study ● CALGARY, Alberta, May 05, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharma...
XRTX:CC - XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial

CALGARY, Alberta, May 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce t...

XRTX:CC - XORTX Receives Small and Medium Enterprise Status for the European Union

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...

XRTX:CC - XORTX Receives No Objection Letter from Health Canada

CALGARY, Alberta, April 12, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
XRTX:CC - XORTX Announces Grant of US Patent

CALGARY, Alberta, April 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...

XRTX:CC - XORTX Files IND with US FDA

● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX I TSXV: XRTX I Frankfurt: ANU), a pharmaceutical ...

XRTX:CC - XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney diseas...
Previous 10 Next 10